Full-Time

Director – Target Profiling

Translational Research

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

This role is expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Lab & Research
Medical Research

You match the following Moderna's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. in a relevant scientific discipline (e.g., oncology, immunology, cancer biology, immune-oncology) with a minimum of 10 years of experience in translational research within the pharmaceutical or biotechnology industry, preferably in immune-oncology or autoimmune therapeutic areas.
  • Proven expertise in developing and validating CDx assays and disease monitoring tools.
  • Strong background in developing flow cytometry, ctDNA sequencing, MRD methodologies, and protein-based assays to inform clinical development.
  • Excellent communication and collaboration skills, with experience working in cross-functional teams.
  • A results-driven mindset, capable of thriving in a fast-paced, innovative environment.
  • Demonstrated ability to innovate translational approaches for novel therapeutic concepts or modalities.
  • Excellent project management and organizational skills, with the ability to manage multiple cancer vaccine projects simultaneously.
  • Strong leadership and interpersonal skills, with the ability to influence and lead cross-functional teams.
  • Demonstrated proficiency in effectively managing and developing direct reports.
  • Exceptional communication skills, both written and verbal, with the ability to effectively convey complex scientific information related to cancer vaccines to a variety of audiences.
Responsibilities
  • Develop and validate cutting-edge methodologies, including ctDNA, MRD, and protein-based assays, to monitor disease progression and therapeutic efficacy in a variety of clinical settings and disease indications.
  • Lead the development of stage-appropriate CDx assays to enable precision patient profiling and inform strategies for therapeutic intervention.
  • Manage the implementation of flow cytometry and other advanced profiling techniques to characterize and/or stratify patient populations effectively.
  • Collaborate with Preclinical Program teams, Translational Medicine and Clinical Biomarker teams to define and implement comprehensive translational strategies to drive programs from concept to clinic.
  • Stay at the forefront of scientific and technological advancements in precision targeting and companion diagnostics.
  • Contribute to the broader translational research team strategy, fostering innovation and excellence.
  • Oversee relationships with CROs and internal labs to ensure the timely completion of assay development, qualification, and validation studies, delivering high-quality data for translational research projects.
  • Mentor and develop junior scientists within the translational research team, fostering a culture of scientific excellence and continuous learning.
  • Act as a scientific liaison and thought partner for key internal and external collaborators, including development and regulatory colleagues, academic institutions, and industry collaborators in the oncology space.
  • Contribute to the preparation of regulatory submissions, scientific publications, and presentations, effectively communicating translational research outcomes.
Desired Qualifications
  • Experience with regulatory submissions and interactions with health authorities is highly desirable.
  • A strong publication record in peer-reviewed journals is preferred, particularly in the field of cancer immunotherapy or autoimmunity.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for various diseases. Unlike traditional pharmaceuticals that often rely on proteins or antibodies, Moderna's mRNA-based therapies can be designed and manufactured more rapidly, allowing for quicker responses to emerging health challenges. The company's goal is to harness the power of mRNA to improve patient outcomes and transform the landscape of medicine.

Company Stage

IPO

Total Funding

$6.5B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

0%

1 year growth

2%

2 year growth

4%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna awarded $590 million for bird flu vaccine development.
  • Moderna's mRNA technology expands into oncology and rare diseases.
  • Moderna's EU tender diversifies COVID-19 vaccine supply.

What critics are saying

  • Increased competition from BioNTech and Pfizer in mRNA vaccines.
  • Potential public skepticism reduces COVID-19 vaccine demand.
  • Regulatory challenges in obtaining approvals for new mRNA vaccines.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.
  • Moderna's collaboration with AI firms enhances drug discovery processes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend